FDA adds vision-loss warning to Ozempic, Wegovy and other GLP-1 drugs

By Olivia Hart

The FDA has required every maker of currently marketed GLP-1 receptor agonists to add a warning about sudden vision loss from nonarteritic anterior ischemic optic neuropathy (NAION). Labels for Ozempic, Wegovy, Zepbound, Mounjaro, Foundayo—Eli Lilly’s new GLP-1 pill—and older GLP-1 agonists will carry the notice in the “warnings and precautions” section.

The FDA wrote: “NAION cases have been reported for all currently marketed GLP-1 [receptor agonist] products.” For manufacturers, the action converts a class-wide safety concern into a prescription-label requirement across diabetes and weight-management medicines. It does not declare vision loss a common outcome.

What does NAION mean for patients?

The FDA describes NAION as an uncommon condition that can cause sudden decreased vision in one eye and, in some cases, permanent vision loss. The condition occurs when blood flow to the front of the optic nerve decreases, although the FDA says its causes are not fully understood.

The FDA report lists smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease as possible NAION risk factors. Because GLP-1 medicines are prescribed for both diabetes and weight management, some underlying risks overlap with conditions the drugs treat. In plain terms, the warning identifies a rare but consequential risk; it does not mean vision loss is common.

What does the evidence establish?

The FDA began examining the link after a 2024 observational study found that semaglutide use in patients with diabetes was associated with NAION. An observational design can identify an association but cannot prove that semaglutide-based GLP-1 drugs caused vision loss.

The agency nevertheless launched a comprehensive evaluation covering clinical-trial data, animal data, case reports and other observational studies. The review tests a signal from several evidence streams, but it does not erase the design limits of the study that prompted it.

GLP-1 medicines treat diabetes and obesity. The cited Brown University research addresses addiction, while the source also identifies kidney disease as another area of research for these drugs. As prescribing expands, continued safety learning could bring additional warning labels, and the FDA’s broader review leaves that possibility open.

That possibility reflects unresolved evidence, not proof of broader harm. In plain terms, regulators have found a safety signal but have not established that GLP-1 drugs cause NAION.

How large is the risk?

The European Medicines Agency reached a similar association finding last year. It wrote: “Results from several large epidemiological studies suggest that exposure to semaglutide in adults with type 2 diabetes is associated with an approximately two-fold increase in the risk of developing NAION compared with people not taking the medicine.”

The EMA recommended that semaglutide medicines include a side-effect warning categorized as very rare and said the condition could affect 1 in 10,000 people using the drugs. That estimate applies to semaglutide exposure among adults with type 2 diabetes, not a measured rate for every GLP-1 product.

The FDA likewise characterized the vision-loss risk as very low but statistically significant enough to report. It cited published literature putting NAION incidence in the general population at 2.3 to 10.2 cases per 100,000 persons per year in adults older than age 50.

On a 10,000-person frame, that baseline equals roughly 0.023 to 0.102 cases annually among adults over 50. It is not a GLP-1-specific incidence estimate, so it cannot be compared directly with the EMA’s semaglutide figure. Both regulators describe the observed risk as very low or very rare, but their numbers measure different populations and should not be treated as interchangeable.

What should patients do?

The FDA advises anyone with sudden, painless changes in vision in one eye to report symptoms immediately to a health provider. The cited FDA summary gives no routine-screening, treatment or drug-discontinuation protocol. It does not say the symptom is unique to GLP-1 medicines.

The FDA says NAION has incompletely understood causes and lists several recognized risk factors. Further research and wider prescribing will test whether the association holds after diabetes, obesity and other risk factors are accounted for.

The FDA’s broader safety process could produce additional labels. The action taken now rests on reported cases and statistical association, not a proven class-wide causal effect.